◎ Sugi Atlas

Atlas / Disease / Pulmonary emphysema

Pulmonary emphysema

disease
On this page

Also known as emphysemaemphysema, pulmonary

Summary

Pulmonary emphysema (MONDO:0004849) is a disease (an umbrella term covering 5 Mondo subtypes) with 10 cohort genes (37 GWAS associations across 45 studies) and 284 clinical trials. Top therapeutic interventions include formoterol, arformoterol, and sildenafil.

At a glance

  • Umbrella term: 5 Mondo subtypes
  • Cohort genes: 10
  • GWAS associations: 37
  • ClinVar variants: 2
  • Clinical trials: 284

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepulmonary emphysema
Mondo IDMONDO:0004849
EFOEFO:0000464
MeSHD004646, D011656
DOIDDOID:9675
ICD-10-CMJ43
NCITC3348
SNOMED CT87433001
UMLSC0034067
MedGen18764
Is cancer (heuristic)no

Also known as: emphysema · emphysema, pulmonary

Data availability: 2 ClinVar variants · 37 GWAS associations (45 studies).

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › obstructive lung disease › chronic obstructive pulmonary disease › pulmonary emphysema

Related subtypes (4): bronchiectasis, chronic bronchitis, diffuse panbronchiolitis, COPD, severe early onset

Subtypes (5): interstitial emphysema, compensatory emphysema, hyperlucent lung, emphysema, hereditary pulmonary, congenital lobar emphysema

Genetics & variants

GWAS landscape

37 GWAS associations across 45 studies. Top hits map to 11 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs174862784e-46CHRNA5A0.19
chr15:789145347e-44C0.19
chr14:943786101e-20?0.83
rs131416412e-15KRT18P51 - HHIP-AS1T0.11
rs1126352998e-15SERPINA2 - SERPINA1G0.34
rs1869947218e-12MFSD9C1.09
chr15:786188391e-11?0.17
rs76982502e-10PPARGC1A - DHX15T0.46
rs104116191e-09ZNF490 - RPL10P16T0.18
chr15:785960588e-09?0.16
rs1170842799e-09PIBF1?1.37
rs72210593e-08MGAT5B - Metazoa_SRPC0.33
rs1426598168e-08SNAI1 - SCREEM1?0.94
rs73392771e-07KLF12?0.76
rs68974832e-07UBL5P1 - ZCCHC10P2?0.43
rs735476402e-07SOX21-AS1 - LINC00557?1.4
rs22406512e-07AP3D1?
rs567845113e-07KCNJ3?0.71
rs67194553e-07KCNJ3?0.57
rs6415255e-07LINC03021 - CSMD1T2.19
rs667714025e-07GLI3 - LINC01448?0.36
rs108441546e-07BICD1C1.46
rs24176617e-07SLC25A6P5 - LINC01505?1.51
rs79055378e-07LINC02629 - PARD3A1.85
rs764703129e-07STC1 - RNU1-148P?1.2
rs1436754981e-06CDH18?1.42
rs92923942e-06HPRT1P2 - RPL19P11T1.83
rs1490866772e-06FBLN2?0.9
rs798797802e-06RNU6-66P - RNU4-10P?1
rs10120365e-06RN7SL292P - SGO1P2C1.47

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90042674Jiang L202145,946351,009A generalized linear mixed model association tool for biobank-scale data.
GCST90078261Backman JD202144,472375,126Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90082247Backman JD202144,472375,126Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90042687Jiang L202125,054392,709A generalized linear mixed model association tool for biobank-scale data.
GCST90078277Backman JD202124,686399,001Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90082263Backman JD202124,686399,001Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90476028Verma A202411,658426,590Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90078293Backman JD202110,430361,302Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90082279Backman JD202110,430361,302Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90042701Jiang L202110,227346,364A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic32

MAF distribution

BucketVariants
common (>=0.05)20
low_freq (0.01-0.05)4
rare (<0.01)1
unknown7

Functional consequences

ConsequenceCount
intron_variant15
intergenic_variant12
unknown4
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs174862781578575140A>C0.319intron_variantCHRNA54e-46Tier 4: intronic/intergenic
chr15:789145340.3667e-44Tier 4: intronic/intergenic
chr14:943786101e-20Tier 4: intronic/intergenic
rs131416414144585304T>A,C0.41intron_variantKRT18P51 - HHIP-AS12e-15Tier 4: intronic/intergenic
rs1126352991494371805G>A,C,T0.018intron_variantSERPINA2 - SERPINA18e-15Tier 4: intronic/intergenic
rs1869947212102732961C>T0.004intron_variantMFSD98e-12Tier 4: intronic/intergenic
chr15:786188391e-11Tier 4: intronic/intergenic
rs7698250424514008C>T0.027intergenic_variantPPARGC1A - DHX152e-10Tier 4: intronic/intergenic
rs104116191912641611T>C0.044intergenic_variantZNF490 - RPL10P161e-09Tier 4: intronic/intergenic
chr15:785960588e-09Tier 4: intronic/intergenic
rs1170842791372870347T>A,C0.05intron_variantPIBF19e-09Tier 4: intronic/intergenic
rs72210591776992362C>A0.026intergenic_variantMGAT5B - Metazoa_SRP3e-08Tier 4: intronic/intergenic
rs1426598162050018625G>Aintergenic_variantSNAI1 - SCREEM18e-08Tier 4: intronic/intergenic
rs73392771373775991G>A,C0.05intron_variantKLF121e-07Tier 4: intronic/intergenic
rs6897483529734966A>G,T0.05intergenic_variantUBL5P1 - ZCCHC10P22e-07Tier 4: intronic/intergenic
rs735476401394879057T>A,C0.05intergenic_variantSOX21-AS1 - LINC005572e-07Tier 4: intronic/intergenic
rs2240651192113274G>A,C,T0.05intron_variantAP3D12e-07Tier 4: intronic/intergenic
rs567845112154785257A>G0.05intron_variantKCNJ33e-07Tier 4: intronic/intergenic
rs67194552154784114C>A0.05intron_variantKCNJ33e-07Tier 4: intronic/intergenic
rs64152582882980T>G0.05intron_variantLINC03021 - CSMD15e-07Tier 4: intronic/intergenic
rs66771402742527478C>G,T0.05intergenic_variantGLI3 - LINC014485e-07Tier 4: intronic/intergenic
rs108441541232227567A>C,G,T0.42non_coding_transcript_exon_variantBICD16e-07Tier 4: intronic/intergenic
rs24176619105918965A>G,T0.05intergenic_variantSLC25A6P5 - LINC015057e-07Tier 4: intronic/intergenic
rs79055371033942347A>C,T0.25intergenic_variantLINC02629 - PARD38e-07Tier 4: intronic/intergenic
rs76470312824029710A>Gintergenic_variantSTC1 - RNU1-148P9e-07Tier 4: intronic/intergenic
rs143675498519849940A>G,Tintron_variantCDH181e-06Tier 4: intronic/intergenic
rs9292394530661466G>A,C,T0.22intron_variantHPRT1P2 - RPL19P112e-06Tier 4: intronic/intergenic
rs149086677313587575G>Aintron_variantFBLN22e-06Tier 4: intronic/intergenic
rs798797801373125266C>A,T0.05intergenic_variantRNU6-66P - RNU4-10P2e-06Tier 4: intronic/intergenic
rs1012036752404754C>T0.23intergenic_variantRN7SL292P - SGO1P25e-06Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 conflicting classifications of pathogenicity, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
691941NM_014681.6(DHX34):c.466C>T (p.Gln156Ter)DHX34Likely pathogenicno assertion criteria provided
599283NM_002317.7(LOX):c.760G>A (p.Val254Ile)SRFBP1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
MAN2B1Orphanet:309282Alpha-mannosidosis, infantile form
MAN2B1Orphanet:309288Alpha-mannosidosis, adult form

Cohort genes → proteins

10 cohort genes, 10 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only8
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
BICD1HGNC:1049ENSG00000151746Q96G01Protein bicaudal D homolog 1gwas
CSMD1HGNC:14026ENSG00000183117Q96PZ7CUB and sushi domain-containing protein 1gwas
PARD3HGNC:16051ENSG00000148498Q8TEW0Partitioning defective 3 homologgwas
DHX34HGNC:16719ENSG00000134815Q14147Probable ATP-dependent RNA helicase DHX34clinvar
CDH6HGNC:1765ENSG00000113361P55285Cadherin-6gwas
ADARB2HGNC:227ENSG00000185736Q9NS39Inactive double-stranded RNA-specific editase B2gwas
MGAT5BHGNC:24140ENSG00000167889Q3V5L5Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase Bgwas
SRFBP1HGNC:26333ENSG00000151304Q8NEF9Serum response factor-binding protein 1clinvar
DHX15HGNC:2738ENSG00000109606O43143ATP-dependent RNA helicase DHX15gwas
MAN2B1HGNC:6826ENSG00000104774O00754Lysosomal alpha-mannosidasegwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
BICD1Protein bicaudal D homolog 1Regulates coat complex coatomer protein I (COPI)-independent Golgi-endoplasmic reticulum transport by recruiting the dynein-dynactin motor complex.
CSMD1CUB and sushi domain-containing protein 1Potential suppressor of squamous cell carcinomas.
PARD3Partitioning defective 3 homologAdapter protein involved in asymmetrical cell division and cell polarization processes.
DHX34Probable ATP-dependent RNA helicase DHX34Probable ATP-binding RNA helicase required for nonsense-mediated decay (NMD) degradation of mRNA transcripts containing premature stop codons.
CDH6Cadherin-6Cadherins are calcium-dependent cell adhesion proteins.
ADARB2Inactive double-stranded RNA-specific editase B2Single- and double-stranded RNA-binding protein that interferes with the RNA editing activities of ADAR/ADAR1 and ADARB1/ADAR2.
MGAT5BAlpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase BGlycosyltransferase that acts on alpha-linked mannose of N-glycans and O-mannosyl glycans.
SRFBP1Serum response factor-binding protein 1May be involved in regulating transcriptional activation of cardiac genes during the aging process.
DHX15ATP-dependent RNA helicase DHX15RNA helicase involved in mRNA processing and antiviral innate immunity.
MAN2B1Lysosomal alpha-mannosidaseCan hydrolyze a variety of glycan substrates containing terminal alpha-mannosidic linkages.

Protein-family classification

Druggable: 2 · Difficult: 2 · Unknown: 6 · Druggable fraction: 0.2

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Complement126.8×0.184
Scaffold/PPI11.7×0.725
Enzyme (other)11.2×0.725
Other/Unknown61.1×0.725
Transcription factor10.8×0.725

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
BICD1Other/UnknownnoBICD
CSMD1ComplementyesSushi_SCR_CCP_dom, CUB_dom, Sperma_CUB_dom_sf
PARD3Scaffold/PPInoPDZ, Par3/HAL_N, PDZ_sf
DHX34Transcription factorno3.6.4.13Helicase_C-like, Helicase-assoc_dom, DEAD/DEAH_box_helicase_dom
CDH6Other/UnknownnoCadherin_Y-type_LIR, Cadherin-like_dom, Cadherin-like_sf
ADARB2Other/UnknownnoA_deamin, dsRBD_dom, ADAR3_DSRM_1
MGAT5BOther/UnknownnoGT18_cat, MGAT5_Glycosyltransferase
SRFBP1Other/UnknownnoBud22_dom, Bud22/SRFB1
DHX15Other/UnknownnoHelicase_C-like, DNA/RNA_helicase_DEAH_CS, Helicase-assoc_dom
MAN2B1Enzyme (other)yes3.2.1.24Glyco_hydro_38_N, Gal_mutarotase_sf_dom, Glyco_hydro/deAcase_b/a-brl

Expression context

Cohort genes with no expression data: 0.

10 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)10
unknown0

Top tissues across cohort

TissueCohort genes
tongue squamous epithelium2
ganglionic eminence1
sural nerve1
ventricular zone1
Brodmann (1909) area 231
middle temporal gyrus1
primary visual cortex1
cervix squamous epithelium1
secondary oocyte1
blood1
left testis1
right testis1
olfactory bulb1
type B pancreatic cell1
C1 segment of cervical spinal cord1
spinal cord1
substantia nigra1
Brodmann (1909) area 91
oocyte1
right frontal lobe1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
BICD1259ubiquitousmarkerventricular zone, sural nerve, ganglionic eminence
CSMD1179broadmarkerBrodmann (1909) area 23, middle temporal gyrus, primary visual cortex
PARD3278ubiquitousmarkercervix squamous epithelium, tongue squamous epithelium, secondary oocyte
DHX34217ubiquitousmarkerright testis, blood, left testis
CDH6228broadmarkerolfactory bulb, type B pancreatic cell, tongue squamous epithelium
ADARB2184broadmarkerC1 segment of cervical spinal cord, spinal cord, substantia nigra
MGAT5B158broadmarkerright frontal lobe, Brodmann (1909) area 9, oocyte
SRFBP1235ubiquitousmarkercalcaneal tendon, male germ line stem cell (sensu Vertebrata) in testis, colonic epithelium
DHX15295ubiquitousmarkercartilage tissue, tibia, germinal epithelium of ovary
MAN2B1138ubiquitousmarkerbone marrow cell, granulocyte, monocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
DHX155,376
PARD33,034
SRFBP12,607
DHX342,501
MGAT5B2,104
CSMD11,577
BICD11,462
ADARB21,322
CDH61,169
MAN2B11,077

Structural data

PDB: 4 · AlphaFold-only: 6 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
DHX15O431439
CSMD1Q96PZ71
PARD3Q8TEW01
CDH6P552851

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
MAN2B1O0075491.78
MGAT5BQ3V5L582.58
DHX34Q1414780.85
BICD1Q96G0172.36
ADARB2Q9NS3971.69
SRFBP1Q8NEF962.20

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 10 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Lysosomal oligosaccharide catabolism1475.8×0.029MAN2B1
DAG1 core M2 glycosylations1380.7×0.029MGAT5B
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)1112.0×0.065PARD3
Tight junction interactions161.4×0.087PARD3
Adherens junctions interactions141.4×0.087CDH6
Cell-cell junction organization141.4×0.087CDH6
COPI-independent Golgi-to-ER retrograde traffic134.6×0.087BICD1
Cell junction organization131.2×0.087CDH6
Cell-Cell communication122.9×0.095CDH6
Golgi-to-ER retrograde transport122.1×0.095BICD1
Metabolism of carbohydrates and carbohydrate derivatives120.0×0.095MAN2B1
CHD1 and CHD2 subfamily118.1×0.095DHX15
Intra-Golgi and retrograde Golgi-to-ER traffic117.5×0.095BICD1
mRNA Polyadenylation114.6×0.104DHX15
mRNA Splicing - Major Pathway19.1×0.154DHX15
Dengue Virus-Host Interactions17.6×0.171DHX15
Membrane Trafficking16.2×0.196BICD1
Vesicle-mediated transport15.8×0.196BICD1
Innate Immune System14.2×0.247MAN2B1
Neutrophil degranulation13.9×0.257MAN2B1
Immune System12.2×0.401MAN2B1
Metabolism11.9×0.417MAN2B1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 10 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
microtubule anchoring at microtubule organizing center1842.6×0.020BICD1
negative regulation of mRNA modification1842.6×0.020ADARB2
negative regulation of phospholipase C-activating G protein-coupled receptor signaling pathway1842.6×0.020BICD1
RNA processing243.8×0.020BICD1, ADARB2
oviduct epithelium development1561.7×0.023CSMD1
mammary gland branching involved in pregnancy1421.3×0.023CSMD1
minus-end-directed organelle transport along microtubule1421.3×0.023BICD1
adenosine to inosine editing1337.0×0.023ADARB2
negative regulation of peptidyl-threonine phosphorylation1337.0×0.023PARD3
constitutive secretory pathway1280.9×0.023BICD1
asymmetric cell division1240.7×0.023PARD3
positive regulation of protein localization to centrosome1240.7×0.023BICD1
mannose metabolic process1210.7×0.023MAN2B1
intracellular mRNA localization1210.7×0.023BICD1
negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay1187.2×0.023DHX34
establishment of centrosome localization1168.5×0.023PARD3
conditioned place preference1168.5×0.023CSMD1
virion assembly1153.2×0.023BICD1
response to alkaloid1153.2×0.023DHX15
mRNA processing215.8×0.023ADARB2, DHX15
establishment of epithelial cell polarity1120.4×0.027PARD3
startle response1112.3×0.028CSMD1
glycoprotein catabolic process1105.3×0.028MAN2B1
myelination in peripheral nervous system188.7×0.030PARD3
positive regulation of phosphorylation184.3×0.030DHX34
female gonad development180.2×0.030CSMD1
positive regulation of receptor-mediated endocytosis180.2×0.030BICD1
nuclear-transcribed mRNA catabolic process176.6×0.030DHX34
maturation of SSU-rRNA176.6×0.030SRFBP1
positive regulation of myelination176.6×0.030PARD3

Therapeutics

Drugs indicated for this disease

2 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
BudesonideApproved (phase 4)
Fluticasone PropionateApproved (phase 4)
ArformoterolPhase 3 (in late-stage trials)
BasiliximabPhase 3 (in late-stage trials)
FormoterolPhase 3 (in late-stage trials)
SalmeterolPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Belimumab, Ibuprofen, Isotretinoin, Sodium Chloride, Tretinoin.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 2 · Undrugged: 8

Druggability breadth: 2 of 10 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
DHX1512
MAN2B112
BICD100
CSMD100
PARD300
DHX3400
CDH600
ADARB200
MGAT5B00
SRFBP100

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
MOLIBRESIB2DHX15
TRIDOLGOSIR2MAN2B1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
MAN2B153Binding:52, ADMET:1
DHX1510Binding:10

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
DHX343.6.4.13RNA helicase
MAN2B13.2.1.24alpha-mannosidase

Pharmacogenomics

Cohort genes with a PharmGKB record: 10; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

2 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
MOLIBRESIB2DHX15
TRIDOLGOSIR2MAN2B1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved2DHX15, MAN2B1
CDruggable family + PDB, no drug1CSMD1
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug7BICD1, PARD3, DHX34, CDH6, ADARB2, MGAT5B, SRFBP1

Undrugged target profiles

8 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
BICD10—
CSMD10—
PARD30—
DHX340—
CDH60—
ADARB20—
MGAT5B0—
SRFBP10—

Clinical trials & evidence

Clinical trials

Clinical trials: 284.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified187
PHASE231
PHASE423
PHASE316
PHASE111
PHASE1/PHASE28
PHASE2/PHASE36
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02682147PHASE4ACTIVE_NOT_RECRUITINGFunctional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
NCT07326592PHASE4NOT_YET_RECRUITINGPhase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
NCT00175565PHASE4COMPLETEDInhaled Steroid Reduces Systemic Inflammation in COPD
NCT00181207PHASE4COMPLETEDAirway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
NCT00261833PHASE4COMPLETEDZemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
NCT00424528PHASE4COMPLETEDEfficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00633776PHASE4WITHDRAWNPerforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)
NCT00670007PHASE4COMPLETEDExtension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
NCT00680056PHASE4COMPLETEDAdd-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
NCT00680641PHASE4UNKNOWNSimvastatin in Chronic Obstructive Pulmonary Disease (COPD)
NCT00720226PHASE4COMPLETEDEfficacy of Losartan in Preventing Progression of COPD
NCT00730301PHASE4UNKNOWNEUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema
NCT00857038PHASE4UNKNOWNDoxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
NCT01336283PHASE4COMPLETEDEffectiveness of Different Exercise Training Programs to the Profile of COPD Patients
NCT01361984PHASE4UNKNOWNSunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
NCT01431625PHASE4UNKNOWNEffects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype
NCT01460108PHASE4UNKNOWNAeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation
NCT01466712PHASE4UNKNOWNEvaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function
NCT01520740PHASE4TERMINATEDCollateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema
NCT02696564PHASE4COMPLETEDLosartan Effects on Emphysema Progression
NCT03073798PHASE4COMPLETEDThe Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
NCT03382106PHASE4COMPLETEDSmoking Cessation and Functional CT Assessment
NCT03733470PHASE4COMPLETEDHypoxic Pulmonary Vasoconstriction Pilot Study
NCT00000606PHASE3COMPLETEDNational Emphysema Treatment Trial (NETT)
NCT00064402PHASE3COMPLETEDDetermine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
NCT00064415PHASE3COMPLETEDTo Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
NCT00129584PHASE3COMPLETEDEndobronchial Valve for Emphysema Palliation Trial (VENT)
NCT00137956PHASE3TERMINATEDEndobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study
NCT00188825PHASE3COMPLETEDStudy Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant
NCT00207337PHASE2/PHASE3COMPLETEDExhale (R) Stent for Emphysema
NCT00250679PHASE3COMPLETEDSafety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
NCT00288964PHASE3WITHDRAWNUse of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
NCT00391612PHASE3UNKNOWNEASE Trial: Exhale Airway Stents for Emphysema
NCT00613860PHASE3WITHDRAWNSequential Endoscopic Lung Volume Reduction
NCT00995852PHASE2/PHASE3UNKNOWNUnilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study
NCT01181466PHASE2/PHASE3COMPLETEDAeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema
NCT01217671PHASE2/PHASE3COMPLETEDInternational Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema
NCT01320566PHASE2/PHASE3TERMINATEDA Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
NCT01421082PHASE2/PHASE3COMPLETEDEvaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema
NCT01449292PHASE3TERMINATEDStudy of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
FORMOTEROL47
ARFORMOTEROL46
SILDENAFIL46
LOSARTAN44
TIOTROPIUM44
.ALPHA.1-PROTEINASE INHIBITOR HUMAN43
DOXYCYCLINE ANHYDROUS43
SALMETEROL43
BASILIXIMAB41
BECLOMETHASONE DIPROPIONATE41
BELIMUMAB41
ROFLUMILAST41
SIMVASTATIN41
TRETINOIN41
XENON XE-129, HYPERPOLARIZED41
ABAMECTIN32
QUERCETIN31
ALVELESTAT21
BECLOMETHASONE21
RETINOIC ACID RECEPTOR .GAMMA.21
VAPENDAVIR21
CHEMBL465075502
CHEMBL430343001
CHEMBL479271801
CHEMBL543965101

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgwasgwas_studyhgncicd10cmintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot